Kamada Ltd. Expected to Post Q3 2024 Earnings of $0.07 Per Share (NASDAQ:KMDA)

Kamada Ltd. (NASDAQ:KMDA) – Research analysts at HC Wainwright lifted their Q3 2024 earnings per share estimates for Kamada in a report issued on Thursday, August 15th. HC Wainwright analyst A. Fein now expects that the biotechnology company will earn $0.07 per share for the quarter, up from their prior forecast of $0.05. HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Kamada’s current full-year earnings is $0.24 per share. HC Wainwright also issued estimates for Kamada’s Q4 2024 earnings at $0.08 EPS, FY2027 earnings at $0.50 EPS and FY2028 earnings at $0.57 EPS.

A number of other equities analysts also recently issued reports on the company. StockNews.com initiated coverage on Kamada in a report on Sunday, July 21st. They issued a “buy” rating for the company. Stifel Nicolaus started coverage on Kamada in a report on Wednesday, July 3rd. They issued a “buy” rating and a $18.00 price objective for the company.

Kamada Stock Up 3.2 %

Shares of KMDA opened at $5.54 on Monday. The stock has a 50 day moving average price of $5.44 and a 200 day moving average price of $5.55. The company has a market capitalization of $318.44 million, a price-to-earnings ratio of 24.09 and a beta of 1.06. Kamada has a 52-week low of $4.08 and a 52-week high of $6.53.

Institutional Investors Weigh In On Kamada

Several large investors have recently modified their holdings of the company. Y.D. More Investments Ltd boosted its holdings in shares of Kamada by 1,956.0% in the second quarter. Y.D. More Investments Ltd now owns 726,161 shares of the biotechnology company’s stock valued at $3,643,000 after acquiring an additional 690,842 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Kamada by 8.2% in the first quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock valued at $7,433,000 after acquiring an additional 100,800 shares during the period. Aristides Capital LLC boosted its holdings in shares of Kamada by 41.6% in the fourth quarter. Aristides Capital LLC now owns 56,635 shares of the biotechnology company’s stock valued at $347,000 after acquiring an additional 16,635 shares during the period. Calton & Associates Inc. acquired a new stake in shares of Kamada in the fourth quarter valued at approximately $111,000. Finally, EWA LLC acquired a new stake in shares of Kamada in the fourth quarter valued at approximately $68,000. 20.38% of the stock is owned by institutional investors and hedge funds.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.